Skip to content

Phospholipid Absorption of a Milk Phospholipid

Effect of a Milk Phospholipid Supplementation on the Lipid Metabolism in Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01327430
Enrollment
15
Registered
2011-04-01
Start date
2010-05-31
Completion date
2010-06-30
Last updated
2011-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

glycerophosphates, sphingomyelins

Brief summary

The aim of the study is to investigate parameters of the lipid metabolism in plasma and feces of healthy subjects after a dietary supplementation of different dosages of milk phospholipids.

Detailed description

To date the mechanisms for the intestinal absorption of glycerophosphates and sphingolipids are not completely investigated. It is assumed, that sphingolipids and sterols compete for intestinal absorption. In addition it is unclear, if a dietary phospholipid supplementation may influence the phospholipid concentration in plasma. To evaluate the effect of a dietary phospholipid supplementation 15 healthy female subjects received over 10 days daily 3 g of milk phospholipids stirred in a dairy product. During the following 10 days the subjects were supplemented with daily 6 g milk phospholipid. Finally, the subjects received over 10 days 6 g of the milk phospholipid in a dairy product and 2 g of plant sterols serving a commercial product.

Interventions

DIETARY_SUPPLEMENTMilk phospholipid

During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.

Sponsors

University of Jena
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* female * age: between 30 and 45 years

Exclusion criteria

* metabolic diseases * arteriosclerosis * pregnancy and breast feeding

Design outcomes

Primary

MeasureTime frameDescription
Change in plasma phospholipid concentrationafter 0, 10, 20, and 30 daysTotal phospholipid concentration Individual phospholipid concentration (lyso phosphatidylcholine, phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylinositol)

Secondary

MeasureTime frameDescription
Plasma lipidsafter 0,10,20, and 30 daysFatty acid fraction (total fatty acid distribution, phospholipid fatty acid distribution) Cholesterol fraction (total cholesterol, LDL cholesterol, HDL cholesterol) Triacylglycerides fraction
Fecal lipidsafter 0,10,20, and 30 daysFecal lipids (crude fat, total phospholipids, sterols, bile acids)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026